

Treatment Naïve, Chronic HCV

Peginterferon alfa-2b + Weight-based Ribavirin in HCV GT 2,3

Zeuzem S, et al. J Hepatol. 2004;40:993-9.

Peginterferon alfa-2b + Ribavirin for GT 2 or 3

Study Design

- **Study**

- Single arm, open-label, historical-control, phase 4 study
- Conducted in 39 centers in Europe

- **Subjects**

- N = 224 with chronic hepatitis C enrolled (223 treated)
- Treatment naïve adult patients with genotype 2 or 3 HCV

- **Regimens**

- Peginterferon alfa-2b: 1.5 µg/kg/wk + Ribavirin*: 800-1400 mg/d x 24 wks

- **Primary Endpoint**


- Undetectable serum HCV RNA at end of treatment (ETR)
- Undetectable serum HCV RNA 24 wks after cessation of treatment (SVR)

*Ribavirin dosing: <65 kg = 800 mg/d; 65-85 kg = 1000 mg/d; >85-105 kg = 1200 mg/d; >105 kg = 1400 mg/d

Peginterferon alfa-2b + Ribavirin for GT 2 or 3

Results

SVR24 Rates, by Genotype



Peginterferon alfa-2b + Ribavirin for GT 2 or 3

Conclusions

Conclusions: “Treatment for 24 weeks with peginterferon alfa-2b and ribavirin is sufficient in HCV 2 or 3 infected patients. The lower SVR in patients infected with HCV-3 compared with HCV-2 infected patients may be related to higher levels of steatosis in this population.”

This slide deck is from the University of Washington's *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online
www.hepatitisc.uw.edu

Hepatitis Web Study
<http://depts.washington.edu/hepstudy/>

Funded by a grant from the Centers for Disease Control and Prevention.